Navigation Links
Jennerex Reports Positive Phase 1 Results for JX-594 Administered Intravenously
Date:5/20/2010

"xn-person">Andrew R. Haas, M.D., Ph.D., Hospital of the University of Pennsylvania, and investigator on JX-594 Phase 1 trial.

This open-label, dose-escalation study was completed at four sites in the United States and Canada.  A total of 23 patients with solid tumors refractory to standard therapy were enrolled.  Patients received a single treatment at one of five dose levels, with follow-up at periodic intervals.  Six out of eight patients in the higher-dose cohorts evaluable to date (cohorts 3, 4, 5) exhibited disease control as defined by stable disease by RECIST (Response Evaluation Criteria in Solid Tumors) criteria and/or Choi (necrotic) response.  Two out of six patients in the low dose cohorts exhibited disease control (RECIST stable disease) but no responses.  The primary endpoints of the trial included safety and determination of the maximum tolerated dose given through intravenous administration.  No serious adverse events related to JX-594 therapy were reported and no dose-limiting toxicities were reported.  A biomarker analysis further strengthened the finding of dose-dependent replication in tumors following IV administration.

About JX-594

JX-594, currently in Phase 2 clinical trials for liver cancer, is a cancer biotherapeutic product from a proprietary breakthrough class of targeted and armed oncolytic and immunotherapeutic poxviruses.  Tumor destruction and safety was shown in patients with diverse cancer types in three Phase 1 trials; treated patients were end-stage and had no effective therapies available.  JX-594 multiplies selectively within cancer cells, leading to their destruction.  These newly created copies of JX-594 are then released and are able to infect and eradicate other tumor cells
'/>"/>

SOURCE Jennerex, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Jennerex Appoints Bob Ingram Special Advisor and Hires Marty Glick as EVP, Corporate Strategy
2. Jennerex Completes $8.3 Million Series B Financing and Appoints Dr. Cal Stiller as Director
3. Jennerex Appoints Samantha Miller as Vice President of Corporate Development
4. Nature Reviews Publishes Article About Jennerexs Multi-Mechanistic Cancer Therapeutic
5. Jennerex Closes $5 Million First Tranche of Series C Financing
6. Jennerex Completes Over-Subscribed Series C Financing for Aggregate Gross Proceeds of Over $5.5 Million
7. Jennerex Adds Industry Veteran Paul Cleveland to Board of Directors
8. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
9. QMed, Inc. Reports July Medicare SNP Enrollments
10. Phlo Affiliate Reports Expanded Coverage to Oregon Border
11. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2015)... ... 2015 , ... A newly launched business plan contest will ask startup companies ... in life sciences R&D. The Pistoia Alliance President’s Startup Challenge 2015 will see small ... period of expert mentorship from a senior industry figure drawn from the Pistoia Alliance ...
(Date:7/1/2015)...  UCB, a multinational biopharmaceutical company, and Genpact ... designing, transforming, and running intelligent business operations, have ... their close collaboration in driving transformation that achieved ... (GBS) finance organization. The Aecus Innovation ... together effectively to embrace the innovative promise of ...
(Date:6/30/2015)... Clara CA (PRWEB) , ... June 30, 2015 ... ... microscopy (AFM) is hosting a webinar to provide advanced scientific research into new ... science, bio science and energy. Touted as 'the wonder material of the ...
(Date:6/30/2015)... San Francisco, CA (PRWEB) , ... June 30, ... ... in FMT Patients , Study will provide new insights on mechanics of fecal ... announced a new partnership to study the microbiome of patients undergoing fecal microbiota ...
Breaking Biology Technology:Pistoia Alliance Launches Startup Challenge 2Pistoia Alliance Launches Startup Challenge 3UCB and Genpact Receive Aecus Innovation Award for Success in Global Business Services 2UCB and Genpact Receive Aecus Innovation Award for Success in Global Business Services 3UCB and Genpact Receive Aecus Innovation Award for Success in Global Business Services 4UCB and Genpact Receive Aecus Innovation Award for Success in Global Business Services 5How Graphene–based Nanomaterials and Films Revolutionize Science Explained in July 9 Webinar Hosted by Park Systems 2How Graphene–based Nanomaterials and Films Revolutionize Science Explained in July 9 Webinar Hosted by Park Systems 3How Graphene–based Nanomaterials and Films Revolutionize Science Explained in July 9 Webinar Hosted by Park Systems 4uBiome and OpenBiome Partner for Microbiome Study in FMT Patients 2uBiome and OpenBiome Partner for Microbiome Study in FMT Patients 3
... , ATLANTA and LONDON, Sept. 10 ... ) an implantable biological medical device and cardiovascular tissue processing company, ... (R) Surgical Matrix, which received CE mark approval in August ... removal as a supplemental measure to promote hemostasis (a complex process ...
... Md., Sept. 10 DHA omega-3 innovator and maker of the ... ), announced today it has resolved a patent dispute with Capsugel ... in the High Court of Strasbourg, France. , , ... Capsugel France, Capsugel and all of its affiliates have agreed to ...
... Texas, Sept. 10 , , WHO: Panel of leading ... WHEN: Tuesday, September 15th , , 9:50 a.m. ... on eDiscovery for Pharma, Biotech & Medical Device Industries , , ... TOPIC: Cost-Benefit Analysis of In-house eDiscovery Tools vs. Outsourcing Help , , ...
Cached Biology Technology:CryoLife Announces First Clinical Use of BioFoam(R) 2CryoLife Announces First Clinical Use of BioFoam(R) 3CryoLife Announces First Clinical Use of BioFoam(R) 4CryoLife Announces First Clinical Use of BioFoam(R) 5Martek Announces Settlement of Patent Dispute with Capsugel France 2StoredIQ Shares Expertise at IQPC's eDiscovery Pharma, Biotech and Medical Device Conference 2
(Date:6/24/2015)... 24, 2015 Biometry authentication provider KeyLemon ... password solution one face in. ... one face in, entering the expanding biometric authentication ... multifactor-authentication biometric answer to the password problem. With ... partnership with KeyLemon, one face in allows users ...
(Date:6/23/2015)... N.C. , June 23, 2015   ... today announced the results of a recent study ... accuracy on the wrist during activity. In a ... technology was compared along with the Apple Watch ... accurately measuring heart rate during activity. The study ...
(Date:6/18/2015)... Conn. , June 18, 2015 NXT-ID, Inc. ... authentication company focused on the growing mobile commerce market announces ... a featured segment on "Money on the Mark", scheduled to ... City June 20 th . ... will be from 7:00 to 8:00pm EST. NXT-ID, Inc.,s CEO ...
Breaking Biology News(10 mins):KeyLemon Announces Partnership With Biometric Password Solution onefacein 2Valencell Delivers Breakthrough Heart Rate Accuracy on the Wrist 2Valencell Delivers Breakthrough Heart Rate Accuracy on the Wrist 3NXT-ID, Inc.'s CEO Gino Pereira Talks About the Wocket Smart Wallet on WABC Radio, New York City, June 20th 2NXT-ID, Inc.'s CEO Gino Pereira Talks About the Wocket Smart Wallet on WABC Radio, New York City, June 20th 3
... damage depends on the balance between the generation of scar ... significant minority of people who get injury to their organs ... to chronic liver disease and cirrhosis where the scarring is ... produce vital hormones and clotting factors. Liver scars also provide ...
... Barbara, Calif.) The National Institutes of Health (NIH) ... engineering, chemistry, and biology researchers to develop a highly ... The technology provides an entirely new method of discovering ... range of applications, including next-generation disease diagnosis at the ...
... (HGNS) produced marked dose-related increases in airflow in obstructive ... according to a new study from the Johns Hopkins ... efficacy of HGNS across a broad range of sleep ... airway pressure (CPAP), the current mainstay of treatment for ...
Cached Biology News:Researchers awarded $3.2 million from NIH to pioneer advanced biomolecule discovery technology 2Researchers awarded $3.2 million from NIH to pioneer advanced biomolecule discovery technology 3Hypoglossal nerve stimulation increases airflow during sleep in obstructive sleep apnea 2
... you to store and manage very large ... secure central relational database. Storing and managing ... resource for clone tracking and enables you ... analysis. LabShare software integrates seamlessly with Invitrogen's ...
... A and Protein G bind specifically to ... A and Protein G conjugates are commonly ... (antibodies) and immunoglobulin subtypes from serum, hybridoma ... biological fluids. These reagents are also commonly ...
... many of the automation concepts from High ... are similar to those for HTS: ... or 48 wells with well volumes of ... number of wells has increased to 96 ...
... for 0.2ml thermal cycler blocks, 96-well PCR plate, ... and heat seals), Cut-away corner , Fits all ... and 3700 capillary sequencers, Clear well bottom for ... Thermo-Mats, Adhesive Films and Foils, Heat Seals and ...
Biology Products: